Pharmacokinetics

Baseline use of hydroxychloroquine in systemic lupus erythematosus does not preclude SARS-CoV-2 infection and severe COVID-19
Maximilian F Konig, Alfred HJ Kim, Marc H Scheetz, Elizabeth R Graef, Jean W Liew, Julia Simard, Pedro M Machado, Milena Gianfrancesco, Jinoos Yazdany, Daman Langguth, Philip C Robinson

Annals of the Rheumatic Diseases Oct 2020, 79 (10) 1386-1388; DOI: 10.1136/annrheumdis-2020-217690
Correspondence to ‘Hypersensitivity reactions with allopurinol and febuxostat: a study using the Medicare claims data’
Kevin Sheng-Kai Ma, James Cheng-Chung Wei, Wen-Hung Chung

Annals of the Rheumatic Diseases Jun 2020, annrheumdis-2020-218090; DOI: 10.1136/annrheumdis-2020-218090
Response to: ‘Tapering without relapse in rheumatoid arthritis patients with high TNF blocker concentrations: data from the STRASS study’ by Marotte et al
Merel J l'Ami, Charlotte L Krieckaert, Michael T Nurmohamed, Ronald F van Vollenhoven, Theo Rispens, Maarten Boers, Gerrit Jan Wolbink

Annals of the Rheumatic Diseases Jul 2020, 79 (7) e82; DOI: 10.1136/annrheumdis-2019-215609
Can IL-1 be used as a target for osteoarthritis?
Chao Cheng, Jian Tian, Fangjie Zhang

Annals of the Rheumatic Diseases Jul 2020, 79 (7) e88; DOI: 10.1136/annrheumdis-2019-215513
Differing contribution of methotrexate polyglutamates to adalimumab blood levels as compared with etanercept
Thierry Dervieux, Joel M Kremer, Michael E Weinblatt

Annals of the Rheumatic Diseases Sep 2019, 78 (9) 1285-1286; DOI: 10.1136/annrheumdis-2018-214860
Comment on l’Ami et al titled ’Successful reduction of overexposure in patients with rheumatoid arthritis with high serum adalimumab concentrations: an open-label, non-inferiority, randomised clinical trial'
Alfons A den Broeder, Bart J F van den Bemt

Annals of the Rheumatic Diseases Oct 2018, 77 (10) e67; DOI: 10.1136/annrheumdis-2017-212579
In vivo visualisation of different modes of action of biological DMARDs inhibiting osteoclastic bone resorption
Yoshinobu Matsuura, Junichi Kikuta, Yuika Kishi, Tetsuo Hasegawa, Daisuke Okuzaki, Toru Hirano, Masafumi Minoshima, Kazuya Kikuchi, Atsushi Kumanogoh, Masaru Ishii

Annals of the Rheumatic Diseases Aug 2018, 77 (8) 1219-1225; DOI: 10.1136/annrheumdis-2017-212880
Repeated administration of dapirolizumab pegol in a randomised phase I study is well tolerated and accompanied by improvements in several composite measures of systemic lupus erythematosus disease activity and changes in whole blood transcriptomic profiles
Chris Chamberlain, Peter J Colman, Ann M Ranger, Linda C Burkly, Geoffrey I Johnston, Christian Otoul, Christian Stach, Miren Zamacona, Thomas Dörner, Murray Urowitz, Falk Hiepe

Annals of the Rheumatic Diseases Nov 2017, 76 (11) 1837-1844; DOI: 10.1136/annrheumdis-2017-211388
A randomised, single-blind, single-dose, three-arm, parallel-group study in healthy subjects to demonstrate pharmacokinetic equivalence of ABP 501 and adalimumab
Primal Kaur, Vincent Chow, Nan Zhang, Michael Moxness, Arunan Kaliyaperumal, Richard Markus

Annals of the Rheumatic Diseases Mar 2017, 76 (3) 526-533; DOI: 10.1136/annrheumdis-2015-208914
A multicentre randomised controlled trial to compare the pharmacokinetics, efficacy and safety of CT-P10 and innovator rituximab in patients with rheumatoid arthritis
Dae Hyun Yoo, Chang-Hee Suh, Seung Cheol Shim, Slawomir Jeka, Francisco Fidencio Cons-Molina, Pawel Hrycaj, Piotr Wiland, Eun Young Lee, Francisco G Medina-Rodriguez, Pavel Shesternya, Sebastiao Radominski, Marina Stanislav, Volodymyr Kovalenko, Dong Hyuk Sheen, Leysan Myasoutova, Mie Jin Lim, Jung-Yoon Choe, Sang Joon Lee, Sung Young Lee, Taek Sang Kwon, Won Park

Annals of the Rheumatic Diseases Mar 2017, 76 (3) 566-570; DOI: 10.1136/annrheumdis-2016-209540

Main menu

Pharmacokinetics

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

Pharmacokinetics

Pages